• Policy
• Dupixent, Cibinqo, Rinvoq to be reimb for pediatric AD in 1H
• by Lee, Tak-Sun Mar 10, 2023 05:49am

• Policy
• Multiple myeloma CAR-T therapeutic agent CARVYKTI, imminent
• by Lee, Hye-Kyung Mar 9, 2023 06:00am

• Policy
• Gov expands SGLT-2 diabetes drug combi benefit from April
• by Lee, Jeong-Hwan Mar 8, 2023 05:53am

• Policy
• PVA, the higher the bill, the greater the discount rate
• by Lee, Tak-Sun Mar 8, 2023 05:52am

• Policy
• Free vaccination of Rotarix·RotaTeq is available
• by Lee, Jeong-Hwan Mar 7, 2023 05:39am

• Policy
• ‘Improve rare disease designations standards for equity'
• by Lee, Jeong-Hwan Mar 7, 2023 05:38am

• Policy
• ‘RSA may be applied to non-rare innovative new drugs'
• by Lee, Jeong-Hwan Mar 7, 2023 05:38am

• Policy
• Tecentriq fails urothelial carcinoma trial but beneficial
• by Lee, Hye-Kyung Mar 6, 2023 05:56am

• Policy
• Full-fledged competition in the ultra-large market
• by Lee, Tak-Sun Mar 6, 2023 05:56am

• Policy
• GC Biopharma’s Livmarli approved as first ALGS Tx in KOR
• by Lee, Hye-Kyung Mar 2, 2023 05:53am